

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical Technologies Advisory Committee (MTAC)

Minutes of the 76th meeting on Friday 16th February 2018

Level1A City Tower, Piccadilly Plaza, Manchester M1 4BT

Committee members

present:

- Peter Groves (Chair)
- Fiona Denison (Vice-chair)
- Allan Wailoo
- Alun Williams
- Andrew Thorpe
- Avril McCarthy
- Daniel Clark
- Greg Irving
- Jai Patel
- Matthew Campbell-Hill
- Paul Knox
- Shaheen Hamdy
- Chris Hudson
- Susan Bennett
- Karen McCutcheon
- Mohammad Ilyas
- Mike Burrows

Committee member

apologies:

- Amber Young
- Cynthia Iglesias
- John Wilkinson
- Steven Fearn

Medical technologies evaluation programme staff present:

- Mark Campbell, Acting Programme Director
- Bernice Dillon, Technical Adviser
- Paul Dimmock, Technical Adviser
- Neil Hewitt, Technical Analyst
- Liesl Millar, Technical Analyst
- Kim Carter, Technical Analyst
- Sarah Douglas, Technical Analyst
- Tosin Oladapo, Technical Analyst
- Alexia Campbell-Burton, Technical Analyst
- Lee Dobson, Programme Manager
- Izabela Syrek, Administrator

External assessment centre (EAC) representatives present:

- Dr Anastasia Chalkidou, Senior Health Technology Assessor, KiTEC
- Dr Mark Pennington, Senior Health Economist, KiTEC
- Dr Iain Willits, Medical Technologies Evaluator, N&Y
- Mrs Helen Cole, Centre Manager/Head of Service - Clinical Scientist, N&Y

Expert advisers present:

- Dr Antonin Gechev, Consultant Neurophysiologist, Hemel Hempstead Hospital, West Hertfordshire Hospitals NHS Trust
- Prof Solomon Tesfaye, Consultant Diabetologist & Research Director, Sheffield Teaching Hospitals NHS Foundation Trust
- Ms Karen Sanderson, Advanced Nurse Practitioner, Guy's & St Thomas Hospital, Guy's and St Thomas' NHS Foundation Trust
- Mr Alistair Jenkins, Consultant Neurosurgeon, The Royal Victoria Infirmary, The Newcastle Upon Tyne Hospitals NHS Foundation Trust
- Mr Girish Vajramani, Consultant Neurosurgeon, University Hospital Southampton NHS Foundation Trust
- Dr James Lenton, Vascular & Interventional Radiology Consultant, Leeds Teaching Hospitals NHS Trust
- Mr Daniel Carradice, Consultant Vascular & Endovascular Surgeon, Hull York Medical School

Observers present:

- Katie Wyart, Medical Technology Implementation Manager, Adoption and Impact Team, NICE
- Rachel Kettle, Public Health Technical Adviser, Public Health Guidelines Team, NICE
- Eleanor Mollett, Service Delivery Manager, Digital Services, NICE
- Jane Lynn, Business Analyst, Resource Impact Assessment Team, NICE
- Ian Mather, Business Analyst, Resource Impact Assessment Team, NICE
- Gareth Murphy, Business Analyst (Accountant), Resource Impact Assessment Team, NICE
- Jamie Erskine, Health Technology Assessor, KiTEC (King's Technology Evaluation Centre)
- Ina Guri, Research Scientist, Newcastle & York EAC

10.00 – Meeting began

1. Introduction to the meeting

The chairman welcomed all members of the committee and other attendees present to the meeting.

2. News and announcements

The chairman confirmed committee members who have given apologies for the meeting.

3. Minutes of previous meeting

The committee agreed the minutes from the 08 December 2017 committee meeting.

10:10 – Part 1 open session commenced (company representatives, EAC representatives, experts and members of the public were invited into the meeting).

4. MT318 The Neuropad test for the early detection of diabetic peripheral neuropathy – final guidance recommendations

The chairman welcomed the invited experts then rehearsed the code of conduct to the experts and external observers attending the meeting.

The chairman asked all committee members, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Prof Solomon Tesfaye declared a personal specific financial interest as he has received honoraria (less than £1000 a year) for attending advisory board meetings for the manufacturer of the product that finished in 2016.
 - It was agreed that his declaration would not prevent Prof Tesfaye from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.

The topic was introduced by Mr Alun Williams with Dr Antonin Gechev and Prof Solomon Tesfaye providing expert advice.

11:15 – Part 2 closed session commenced (EAC representatives, experts and members of the public were asked to leave the meeting).

The committee then proposed final recommendations on the technology and these recommendations were reached by consensus.

11:30 – 11:35 break

11:35 – Part 1 open session commenced (company representatives, EAC representatives, experts and members of the public were invited into the meeting).

Committee members

present:

- Peter Groves (Chair)
- Fiona Denison (Vice-chair)
- Allan Wailoo
- Alun Williams
- Andrew Thorpe
- Avril McCarthy
- Daniel Clark
- Greg Irving
- Jai Patel
- Matthew Campbell-Hill
- Paul Knox
- Shaheen Hamdy
- Chris Hudson
- Susan Bennett
- Karen McCutcheon
- Mohammad Ilyas
- Mike Burrows

5. MT330 Senza for delivering high frequency spinal cord stimulation to treat chronic neuropathic pain – final guidance recommendations

The chairman welcomed the invited experts and company representatives from Nervo then rehearsed the code of conduct to the members of the public observing the meeting.

The chairman asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Dr Jai Patel declared a personal specific non-financial interest as he is a study co-applicant for a trial of Senza in chronic pain from lower limb ischaemia. The trial has just begun recruitment.
 - It was agreed that his declaration would not prevent Dr Patel from participating in this section of the meeting.
- Mr Andrew Thorpe declared a personal specific non-financial interest as he has received educational support from the manufacturer of a competitor product (Medtronic).
 - It was agreed that his declaration would not prevent Mr Thorpe from participating in this section of the meeting.
- Ms Karen Sanderson declared a personal specific non-financial and a non-personal specific non-financial interest as she has an honorary contract with the manufacturer of the product for educational lectures.

Ms Sanderson also applied for a research grant and is awaiting its approval. The manufacturer of the technology has also sponsored research grants within the research department at Ms Sanderson's place of work.

- It was agreed that her declaration would not prevent Ms Sanderson from participating in this section of the meeting.
- Mr Girish Vajramani declared a personal specific financial and a non-personal specific interest as he has been on the Nevro clinical advisory board, involving occasional meetings for which expenses were covered.

Mr Vajramani's nursing post (the pain physiotherapy) at the University Hospital Southampton was funded by the Company and St Jude Medical for the last 1 year. This post will be funded by the NHS from April 2018. The funding is paid directly to the trust.

- It was agreed that his declaration would not prevent Mr Vajramani from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Prof Daniel Clark with Ms Karen Sanderson, Mr Alistair Jenkins and Mr Girish Vajramani providing expert advice.

14:20 – Part 1 open session ended (company representatives, EAC representatives, experts and members of the public were asked to leave the meeting).

14:25 – Part 2a closed session commenced (company representatives, EAC representatives and members of the public not present at the meeting).

14:35 – Part 2a closed session ended. Part 2b closed session deferred to next MTAC meeting on 23rd March 2018.

14:40 – Part 1 open session commenced (company representatives, EAC representatives, experts and members of the public were invited into the meeting).

Committee members

present:

- Peter Groves (Chair)
- Fiona Denison (Vice-chair)
- Allan Wailoo
- Alun Williams
- Andrew Thorpe
- Avril McCarthy
- Daniel Clark
- Greg Irving
- Jai Patel
- Matthew Campbell-Hill
- Paul Knox
- Shaheen Hamdy
- Chris Hudson
- Susan Bennett
- Karen McCutcheon
- Mohammad Ilyas
- Mike Burrows

6. MT336 The IN.PACT drug-coated balloon for femoro-popliteal peripheral arterial disease – draft guidance recommendations

The chairman welcomed the invited experts and company representatives from Medtronic then rehearsed the code of conduct to the members of the public observing the meeting.

The chairman asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Dr Jai Patel declared a non-personal specific financial interest as he had approached the manufacturer of the technology and applied for a departmental educational grant but has not yet had a response. This grant would be intended to help fund conference attendance by staff in Dr Patel's department.
 - It was agreed that his declaration would not prevent Dr Patel from participating in this section of the meeting.
- Mr Andrew Thorpe declared a personal specific non-financial interest as he had been in receipt of an educational grant from the manufacturer of the technology under consideration. The grant was received 3 years prior to this meeting and involved a visit to a unit for educational purposes relating to sacral nerve stimulation.
 - It was agreed that his declaration would not prevent Mr Thorpe from participating in this section of the meeting.

- Mr Daniel Carradice declared a personal specific non-financial interest as he is a co-investigator of the Basil 3 trial, a multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents, and plain balloon angioplasty.
 - It was agreed that his declaration would not prevent Mr Carradice from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.

The topic was introduced by Dr Greg Irving with Dr James Lenton and Mr Daniel Carradice providing expert advice.

15:45 – Part 2 closed session commenced (company representatives, EAC representatives, experts and members of the public not present at the meeting).

During the closed session the committee agreed that additional input from both experts and the external assessment centre (EAC) was required. The chairman subsequently deferred the topic for an additional Part 1 open session to take place during the next MTAC meeting on 23rd March 2018.

7. Date of the next meeting

The next meeting of the medical technologies advisory committee will be held on Friday 23rd March 2018 and will start promptly at 9:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.

16:30 – Meeting closed